Last reviewed · How we verify
Human immunodeficiency virus infection
Approved treatments
- Tivicay · GSK
Tivicay blocks the integrase enzyme, preventing HIV from integrating its genetic material into the host cell's DNA. - Trogarzo · Taimed Biologics Usa
Trogarzo works by binding to the CD4 receptor on T-cells, preventing HIV from entering and infecting these cells. - Prezista · Janssen Prods
Darunavir works by blocking the protease enzyme, which is essential for the replication of the HIV virus. - Invirase · Saint Michael's Medical Center
- Rescriptor · GSK
- Ziagen · GSK
Abacavir works by mimicking a building block of DNA, tricking the virus into incorporating it into its genetic material and preventing replication. - Sustiva · Bristol-Myers Squibb
Sustiva works by binding to the reverse transcriptase enzyme, preventing the replication of viral RNA. - Epivir · GSK
Epivir works by mimicking the building blocks of DNA to prevent the replication of viral genetic material. - Crixivan · Merck & Co.
Crixivan blocks the replication of HIV by inhibiting the protease enzyme, which is essential for the virus to produce new particles. - Tybost · Gilead Sciences
Tybost works by blocking the enzyme Cytochrome P450 3A, which is responsible for breaking down many other medications. - Intelence · Janssen R And D
Intelence works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus. - Vemlidy · Gilead Sciences
Vemlidy works by inhibiting the HIV reverse transcriptase enzyme, preventing viral replication. - Vitekta · Gilead Sciences
Vitekta blocks the integrase enzyme, preventing HIV from replicating. - Emtriva · Gilead Sciences
Emtriva works by blocking the reverse transcriptase enzyme, which is necessary for HIV to replicate. - Raltegravir (Use RAL as a simplification strategy) · Hospital Carlos III, Madrid
- Retrovir · GSK
Retrovir works by mimicking the natural building blocks of DNA to prevent HIV from replicating. - Fuzeon · Trimeris
- Lexiva · GSK
Lexiva works by blocking the protease enzyme, which is necessary for HIV to replicate. - Viread · Replicor Inc.
- Agenerase · GSK
- Norvir · AbbVie
Norvir works by blocking the cytochrome P450 3A enzyme, which helps increase the levels of other medications in the body. - Videx · Bristol-Myers Squibb
- Viracept · Agouron Pharms
Viracept works by blocking the protease enzyme, which is essential for the replication of HIV. - Reyataz · Bristol-Myers Squibb
Reyataz works by blocking the protease enzyme, which is essential for the replication of HIV. - Kaletra · Abbvie Deutschland Gmbh Co. Kg
Kaletra blocks the protease enzyme, preventing the HIV virus from replicating. - Viramune · Boehringer Ingelheim
Viramune works by binding to the reverse transcriptase enzyme, preventing HIV from replicating. - Biktarvy · Gilead Sciences
Biktarvy works by binding to the integrase enzyme, preventing the HIV virus from integrating its genetic material into the host cell's DNA. - Fuzeon · Roche
- Pifeltro · Merck & Co.
Pifeltro works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus. - Norvir · Saint Michael's Medical Center
- Rescriptor · Pfizer
- Sustiva · Bristol-Myers Squibb
- Tivicay · St Stephens Aids Trust
- Viramune · Boehringer Ingelheim
Clinical guidelines
- FDA label — 1L|2L
BIKTARVY is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. - FDA label — any
Lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 14 days and older.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Human immunodeficiency virus infection patent landscape — cliff calendar, originator estates, attackable patents
- Human immunodeficiency virus infection treatment landscape brief
- Human immunodeficiency virus infection treatment updates RSS
Frequently asked questions about Human immunodeficiency virus infection
What drugs treat Human immunodeficiency virus infection?
Tracked treatments include Tivicay, Trogarzo, Prezista, Invirase, Rescriptor, Ziagen, Sustiva, Epivir.
What is the treatment for Human immunodeficiency virus infection?
Standard treatment for Human immunodeficiency virus infection includes Tivicay, Trogarzo, Prezista, Invirase, Rescriptor. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Human immunodeficiency virus infection?
FDA label publishes guidelines for Human immunodeficiency virus infection. 2 guideline references tracked.
Related
- Treatment landscape: Human immunodeficiency virus infection patent cliff · Human immunodeficiency virus infection CI report
- Treatment: Tivicay · GSK
- Treatment: Trogarzo · Taimed Biologics Usa
- Treatment: Prezista · Janssen Prods
- Treatment: Invirase · Saint Michael's Medical Center
- Treatment: Rescriptor · GSK
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing